Phase 3 N=204 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/Contusions
Primary: Pain on Movement — 33.1; 65.4 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=795 A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 — 52.73; 58.25; 31.21 percentage of participants — p=<0.0001
Phase 4 N=23 Genetic Basis for Variation in the Renal Elimination of Metformin
Other Conditions That May Be A Focus of Clinical Attention
Primary: Renal Clearance of Metformin — 614; 441 mL/min
Phase 3 N=717 A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 — 51.53; 52.55; 28.30; 47.24 percentage of participants — p=<0.0001
Phase 3 N=264 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
Tinea Pedis · Athlete's Foot
Primary: Complete Cure — 63; 81; 19; 2 Participants
N/A N=63 Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy
GERD
Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes
N/A N=100 Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients
Lumbar Spine Surgery
Primary: Number of Patients Enrolled and Recieving Injection — 98 participants
N/A N=68 Blood Flow, Muscle Regeneration and Sarcopenia
Sarcopenia
Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber
Phase 3 N=800 A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6 — 51.46; 61.81; 25.32 percentage of participants — p=<0.0001
Phase 2 N=101 Treatment With Pazopanib for Neoadjuvant Breast Cancer
Neoplasms, Breast
Primary: Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes — 16 Participants
Phase 1 N=40 Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
Obesity
Primary: Changes in the VAS Score From Baseline. — 2.90; 2.70; -10.8; 6.70 mm
Phase 2 N=135 A Study of Econazole Foam 1% in Athlete's Foot
Tinea Pedis · Athlete's Foot
Primary: Complete Cure Rate: Interdigital Disease — 9; 9; 1 Participants
Phase 2 N=29 A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Synovial Tissue Messenger Ribonucleic Acid (mRNA) Expression at Day 28 — -2.73; -2.83; -3.72; -3.96 relative expression unit (REU)
Phase 4 N=100 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study
Metabolic Syndrome
Primary: Treatment Difference in (Postprandial-Fasting) FMD — -0.34; -0.43 % (change FMD) — p=0.766
Phase 3 N=72 A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing
Tooth Extractions
Primary: Time to Hemostasis — 1.9; 9.8; 6.0 Minutes